Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Biodesix is adding a Digital Diagnostics initiative to its lung strategy, building a multimodal platform combining blood-based biomarkers, imaging biomarkers, and AI. The first product is a radiomics-based lung nodule risk assessment test developed with Vanderbilt University and Vanderbilt Health; initial data will be presented at RSNA on December 3, 2026, with commercial availability anticipated in 2028.
Key figures
- Drug Name
- Radiomics-based lung nodule risk assessment test
- Phase Of Trial
- Prospective clinical study STRATIFY (NCT07858552) commencing Q4 2026
- Rsna data presentation
- December 3, 2026
- Commercial availability
- 2028
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.